Melatonin Secretion and Sleep Quality in Spinal Cord Injury Patients

Spinal Cord Injuries Clinical Trial

— MELATETRA  

Official title:

Melatonin Secretion and Sleep Quality in Spinal Cord Injury Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03167801
• Other study ID #: 2016-A00605-46
• Status: Completed
• Start date: July 11, 2017
• Est. completion date: July 31, 2018

Study information

• Verified date: July 2018
• Source: Centre d'Investigation Clinique et Technologique 805
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To evaluate the relationship between secretion of melatonin and sleep quality in spinal cord injury patients versus a database of healthy volunteers.

Description:

Melatonin is a neurohormone secreted by the pineal gland and excreted by the urinary tract. It has a key role in the synchronisation of circadian rhythms including the sleep wake cycle, with a peak secretion around 03:00.

The neural pathway controlling melatonin secretion is long and transits via the thoracic spine. The exact level is not known, but interruption of the connection in patients with lesions of the spinal cord is known to occur.

Tetraplegic patients often complain of insomnia, daytime sleepiness and poor sleep quality but the contribution of melatonin levels to sleep quality has not been explored in large studies, although case reports have shown reduced or abolished melatonin secretion and altered melatonin secretion profiles with delayed peak secretion. Paraplegic patients report fewer sleep difficulties and little is known about melatonin secretion in this group. The investigators hypothesize that sleep abnormalities are related to abnormalities in melatonin secretion and that this is in turn related to the level of the spinal cord injury

The study aims to explore the profiles of melatonin secretion in patients with spinal cord injuries and comparing melatonin profiles with a database of healthy volunteers. The investigators will further analyse the results looking at the severity of spinal cord injury using the Abbreviated Injury Scale (AIS) and the level of the injury. Outcome measures are melatonin secretion profile, sleep complaints measured using the Pittsburgh scale and daytime sleepiness measured using the Epworth sleep scale.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: July 31, 2018
• Est. primary completion date: July 31, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female = 18 years

• Spinal cord injury patient

• All score AIS

• With a chronic lesion (more than 6 months from initial injury)

• Signed informed consent

Exclusion Criteria:

• Pregnant women

• Breast feeding women

• Refusal to participate at study

• Not covered by national health insurance scheme

• Patient unable to give informed consent

• Transmeridian flight crossing more than 3 time zones in the month preceding the study

• Recent treatment with melatonin (< 1 month) or beta blocker

Related Conditions & MeSH terms

• Spinal Cord Injuries
• Wounds and Injuries

Locations

Country	Name	City	State
France	APHP Hôpital Raymond poincaré	Garches	Ile De France

Sponsors (1)

Lead Sponsor	Collaborator
Centre d'Investigation Clinique et Technologique 805

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Urinary 6-sulfatoxy-melatonin (U6SM)	Urinary 6-sulfatoxy-melatonin (U6SM) will be measured during 24 hours	24 hours
Secondary	Sleep quality	Pittsburgh Sleep Quality Index	24 hours
Secondary	Daytime sleepiness	Epworth Sleepiness Scale	24 hours